Goldline Pharmaceutical IPO Subscription Status Day 2
Goldline Pharmaceutical IPO continues to attract strong investor interest on Day 2 of bidding. The SME IPO opened for subscription on May 12, 2026, and will close on May 14, 2026. Investors are closely tracking the latest GMP, subscription numbers, and expected listing gains as demand remains positive in the grey market.
The IPO is listed on the BSE SME platform and consists entirely of a fresh issue.
Goldline Pharmaceutical IPO GMP Today
As per the latest market updates, Goldline Pharmaceutical IPO GMP is around ₹13-₹14 in the grey market. Based on the upper price band of ₹43, the estimated listing price is around ₹56, indicating an expected listing gain of nearly 30%.
The positive GMP reflects strong market sentiment among SME IPO investors.
Goldline Pharmaceutical IPO Subscription Status Day 2
Goldline Pharmaceutical IPO witnessed healthy demand from retail as well as NII investors during the initial bidding sessions. The issue received strong traction due to attractive valuation and positive GMP trends.
Goldline Pharmaceutical IPO Details
ParticularsDetailsIPO Open DateMay 12, 2026IPO Close DateMay 14, 2026Listing PlatformBSE SMEPrice Band₹41 to ₹43 per shareFace Value₹10 per shareIssue Size₹11.61 CroreLot Size3000 SharesMinimum Investment₹2.58 LakhListing DateMay 19, 2026
About Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited operates in the pharmaceutical and healthcare products segment. The company markets a wide range of pharmaceutical formulations and healthcare products across different therapeutic categories.
The company aims to strengthen its market presence and expand operations through the IPO proceeds.
Goldline Pharmaceutical IPO Review
The IPO has gained investor attention mainly because of:
- Positive grey market premium
- SME pharma sector demand
- Affordable issue size
- Strong retail participation
- Growth opportunities in healthcare sector
However, investors should also consider SME liquidity risks and market volatility before investing.
Should You Apply for Goldline Pharmaceutical IPO?
Investors looking for SME IPO opportunities with short-term listing potential are actively tracking Goldline Pharmaceutical IPO. The strong GMP and positive subscription trend indicate favorable market sentiment.
Long-term investors should also evaluate company fundamentals, financial performance, and sector growth before making investment decisions.
Conclusion
Goldline Pharmaceutical IPO Subscription Status Day 2 shows healthy investor participation along with strong GMP momentum. With expected listing gains and strong retail demand, the IPO remains one of the closely watched SME issues currently open in the market.
Stay tuned for the final subscription numbers, allotment status, and listing performance updates.